The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Takeda Canada

Monday Biotech Deal Review: September 27, 2010

Welcome to your Monday Biotech Deal Review. I am very excited to be writing for The Cross-Border Biotech Blog after working with Jeremy behind the scenes over the past three years. [ed. welcome (back) aboard!] It was a busy week for Canadian biotech companies, so let’s get started. Read more of this post

Monday Deal Review: August 24, 2009

B&W_BigNickelThis week saw a few headline deals that we covered at the time, including the Vasogen-Cervus-IntelliPharmaCeutics deal, the move by Takeda Canada to take back ACTOS rights from Lilly, and the Lonza offer for Patheon, but other than that it seems like it was a quiet week everywhere. Still, check out some good stuff after the jump…

Takeda Canada’s Opening Move: Reacquire Rights to Diabetes Drug ACTOS from Eli Lilly Canada

Takeda Canada, which opened in Mississauga in March, bought back the commercial rights to pioglitazone HCl, a type 2 diabetes drug marketed as ACTOS, from Eli Lilly Canada. Financial terms were not disclosed. Lilly had been marketing the drug in Canada under a 1999 worldwide agreement with Takeda.

Takeda Canada general manager Daaron Dohler characterized the move as “Takeda’s first opportunity to establish a commercial presence in Canada.” The company has job postings up for a manager of sales and marketing operations and two marketing directors.

Having said in March that they were targeting an NDS submission for the end of 2009, I wonder if this move points toward another diabetes product… Stay tuned.

Update: FierceBiotech’s post on the transaction this morning also notes the “boost” ACTOS got last week from the results of a comparative study against GSK’s Avandia.

Bookmark and Share

Takeda Comes to Canada

Takeda expanded into Canada today with the establishment of Takeda Canada Inc., which will be headquartered in Mississauga.

Takeda’s primary therapeutic areas include diabetes, cardiovascular disease, CNS disorders, gastroenterology, bone and joint disorders, chronic kidney disease/anemia and gynecological disorders.

Takeda Canada will register and commercialize medicines from Takeda’s portfolio of primary care and specialty products. Takeda Canada intends to file its first New Drug Submission (NDS) by the end of 2009.

Welcome to Canada!

More from the press release after the jump…


Get every new post delivered to your Inbox.

Join 128 other followers